Skip to main content
Home > BioCentury on BioBusiness > Finance/Investment

Chronological Index of : Finance

 Current Issue
  • Valuing CRISPR/Cas9

    Editas seeks the biggest-ever valuation for a preclinical biotech IPO

    Finance Ebb & Flow Valuing CRISPR/Cas9 Table: Earnings on deck Figure: Money Raised in 2016 Editas Medicine Inc. is looking for a $606.9 million postmoney valuation — the highest of any preclinical biotech IPO…

    Published on 2/1/2016
  • Figure: Money Raised in 2016

    Valuing CRISPR/Cas9 Money Raised in 2016 Last week, the biotech industry raised $801 million, bringing to $3.8 billion the total raised year-to-date. In 2015, a total of $110.3 billion was raised, including $56.6 …

    Published on 2/1/2016
  • Table: Earnings on deck

    Valuing CRISPR/Cas9 Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q; (C) EPS for nine months ended Dec. 31, 2014; (D) Fiscal 1Q Company …

    Published on 2/1/2016
  • Emerging in Denmark

    Why Lundbeckfond Emerge is ramping up its early stage investing

    Lundbeck Foundation is ramping up its early stage investing with a focus on academic science from Denmark.

    Published on 2/1/2016
  • Unfinished business

    Why more crossover rounds in January do not herald a return to 2015 levels

    Finance Unfinished business An uptick in crossover-backed private rounds was about the only bright spot in January, but even that may just be the fading glow of days gone by. Last month saw six crossover rounds …

    Published on 2/1/2016
  • Un-Blended

    Why Tarveda and its VCs are all-in on biologic-drug conjugates

    Finance Un-Blended A year after unveiling its Pentarin platform, Tarveda Therapeutics Inc. and its investors have seen enough data to exclusively focus the cancer company on its biologic-drug conjugates. Tarveda (…

    Published on 2/1/2016
  • Figure: Money Raised in 2016

    Venturing to share Money Raised in 2016 Last week, the biotech industry raised $197 million, bringing to $3 billion the total raised year-to-date. In 2015, a total of $110.2 billion was raised, including $56.6 …

    Published on 1/25/2016
  • Table: Earnings on deck

    Venturing to share Earnings on deck At least 16 biotechs and pharmas are expected to report earnings this week. (A) 2014 core EPS; (B) Fiscal 3Q; (C) EPS for nine months ended Dec. 31 Company Date Pre/post mkt…

    Published on 1/25/2016
  • Venturing to share

    Why Abingworth's new fund is solely focused on risk-sharing deals

    Finance Ebb & Flow Venturing to share Figure: Money Raised in 2016 Table: Earnings on deck Abingworth has seen enough success with its clinical risk-sharing investments that it opted to raise a fund dedicated …

    Published on 1/25/2016
  • Platform Twist

    Why crossover investors flocked to DNA synthesis company Twist's series D

    Finance Platform Twist Backers of Twist Bioscience Corp. believe the DNA synthesis company can grow to be the next Illumina Inc. (NASDAQ:ILMN). They might not have to wait long to see whether the public markets …

    Published on 1/25/2016
  • Figure: Money Raised in 2016

    Conference weak Money Raised in 2016 Last week, the biotech industry raised $396 million, bringing to $2.8 billion the total raised year-to-date. In 2015, a total of $110.2 billion was raised, including $56.6 …

    Published on 1/18/2016
  • Table: JPMorgan movers

    Conference weak JPMorgan movers Biotechs presenting at the JPMorgan Healthcare Conference in San Francisco last week were down a median of 6%, in line with the sell-off seen in the BioCentury 100 index. At least …

    Published on 1/18/2016
  • Surfacing with Novartis

    How Novartis deal allows Surface Oncology to develop its own programs

    Finance Surfacing with Novartis Surface Oncology Inc. expects the $170 million in near-term payments from its cancer immunotherapy deal with Novartis AG (NYSE:NVS; SIX:NOVN) will be enough to develop its …

    Published on 1/18/2016
  • Conference weak

    Why biotech's lousy start to 2016 doesn't necessarily signal the end of days

    Ebb & Flow Ebb & Flow Conference weak Figure: Money Raised in 2016 This year's JPMorgan Healthcare Conference was marred by the biotech sector's worst conference week performance in more than two decades. But …

    Published on 1/18/2016
  • Dilution, then solution

    Why Illumina is willing to incur dilution with pan-cancer test newco Grail

    Finance Dilution, then solution Illumina Inc. (NASDAQ:ILMN) thinks early cancer screening is a massive and untapped market for its DNA sequencing capabilities and is willing to incur about four years of dilution to…

    Published on 1/18/2016
  • Sowing season

    Buysiders eyeing big cap clinical milestones in 2016 to seed next growth spurt

    Buysiders are eyeing a slew of big cap clinical milestones and M&A activity to seed the next phase of growth.

    Published on 1/11/2016
  • All-in endocrine

    How Millendo transformed itself into endocrine play with $62M B round, AZ deal

    Finance Ebb & Flow All-in endocrine New biological insights into Atterocor Inc.'s lone compound combined with asset sleuthing by founding VC Frazier Healthcare have morphed the company into Millendo Therapeutics …

    Published on 1/11/2016
  • Figure: Money Raised in 2016

    Paper cuts Money Raised in 2016 Last week, the biotech industry raised $2,325 million, bringing to $2.3 billion the total raised year-to-date. In 2015, a total of $110.2 billion was raised, including $56.6 billion…

    Published on 1/11/2016
  • Figure: Money razed

    Paper cuts Money razed Source: BCIQ: BioCentury Online Intelligence

    Published on 1/11/2016
  • Figure: Biotech fund flows

    Sowing season Biotech fund flows Biotech funds saw net inflows of $6 billion in 2015, despite $1.3 billion of net outflows during 4Q. The December fund flows figure below is provisional. Source: EPFR Global

    Published on 1/11/2016
  • Table: 2016 milestones

    Sowing season 2016 milestones Selected products with clinical or regulatory milestones expected in 2016. (A) Based on estimated completion date on ClinicalTrials.gov; Source: BCIQ: BioCentury Online Intelligence…

    Published on 1/11/2016
  • Table: Approval watch

    Sowing season Approval watch Selected products up for approval in 2016. Source: BCIQ: BioCentury Online Intelligence Company Product Indication Event Milestone AbbVie Inc. (NYSE:ABBV) / Enanta …

    Published on 1/11/2016
  • Table: New products to watch

    Sowing season New products to watch Selected drugs that received regulatory approval in 2015. (A) Prior approvals in parentheses; Source: BCIQ: BioCentury Online Intelligence Company Product Indication 2015 …

    Published on 1/11/2016
  • Table: Postlaunch report

    Sowing season Postlaunch report Two drugs that were first approved in 2014 — both for HCV — cracked $1 billion in 2015. Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) blew way past that mark…

    Published on 1/11/2016
  • Table: Top biotech products

    Sowing season Top biotech products At least 32 drugs developed and marketed by biotechs are expected to have more than $1 billion in 2015 sales. Antivirals from Gilead Sciences Inc. (NASDAQ:GILD) account for seven…

    Published on 1/11/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993